Insider Trading Activity Amyris Inc (NASDAQ:AMRS) – Mauritius) Pte Ltd Maxwell (Major Shareholder Sold 652,513 shares of Stock

36

Insider Trading Activity For Amyris Inc (NASDAQ:AMRS)

, Mauritius) Pte Ltd Maxwell (Major Shareholder of Amyris Inc (NASDAQ:AMRS) reportedly Sold 652,513 shares of the company’s stock at an average price of 0.55 for a total transaction amount of $358,882.15 SEC Form

Insider Trading History For Amyris Inc (NASDAQ:AMRS)

  • On 8/31/2012 L John Doerr, Director, bought 270,270 with an average share price of $3.70 per share and the total transaction amounting to $999,999.00. View SEC Filing
  • On 8/31/2012 John Melo, CEO, sold 668,730 with an average share price of $3.70 per share and the total transaction amounting to $2,474,301.00. View SEC Filing
  • On 12/24/2012 Thani Sheikh Abdullah Bin K Al, Director, bought 3,355,704 with an average share price of $2.98 per share and the total transaction amounting to $9,999,997.92. View SEC Filing
  • On 3/27/2013 Thani Sheikh Abdullah Bin K Al, Director, bought 1,533,742 with an average share price of $3.26 per share and the total transaction amounting to $4,999,998.92. View SEC Filing
  • On 5/24/2013 John Melo, CEO, sold 24,402 with an average share price of $2.85 per share and the total transaction amounting to $69,545.70. View SEC Filing
  • On 5/15/2014 L John Doerr, Director, bought 172,186 with an average share price of $3.02 per share and the total transaction amounting to $520,001.72. View SEC Filing
  • On 5/12/2015 John Melo, CEO, sold 65,575 with an average share price of $2.08 per share and the total transaction amounting to $136,396.00. View SEC Filing
  • Analyst Ratings For Amyris Inc (NASDAQ:AMRS)
    These are 3 Buy Ratings .
    The current consensus rating for Amyris Inc (NASDAQ:AMRS) is Buy (Score: 3.00) with a consensus target price of $3.60 , a potential (609.64% upside)

    Analyst Ratings History For Amyris Inc (NASDAQ:AMRS)

    • On 3/10/2016 Cowen and Company Reiterated Rating Market Perform with a price target of $2.50 to $2.00
    • On 9/28/2016 Singular Research Reiterated Rating Buy with a price target of $2.80
    • On 1/11/2017 Rodman & Renshaw Reiterated Rating Buy with a price target of $4.00
    • On 1/10/2017 HC Wainwright Set Price Target of rating Buy with a price target of $4.00

    About Amyris Inc (NASDAQ:AMRS)
    Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.

    Recent Trading Activity for Amyris Inc (NASDAQ:AMRS)
    Shares of Amyris Inc closed the previous trading session at 0.503 down -0.004 -0.81% with 3,510,091 shares trading hands.

    An ad to help with our costs